Vasopressin and oxytocin receptors in the central nervous system
- PMID: 8853957
- DOI: 10.1615/critrevneurobiol.v10.i1.60
Vasopressin and oxytocin receptors in the central nervous system
Abstract
This review concentrates on the pharmacological properties and the regional distribution of the arginine vasopressin (AVP) and oxytocin (OT) receptors that are present in the central nervous system. Of particular interest are the kinetics and the pharmacological profiles of these receptors that resemble those present at the periphery. However, their transduction mechanisms need to be further investigated. This should be rendered easier by molecular biology technology. The current knowledge of the anatomical distribution of AVP and OT receptors in the brain is reviewed. Also of great interest for double labeling studies will be the receptor antibodies, now being developed. The existence of additional receptors (AVP4-9) is examined, and aspects of the regulation of the receptors' expression in relation to the age, the species, and the hormonal status or following injury are also discussed.
Similar articles
-
Comparison of the pharmacological profiles of arginine vasopressin and oxytocin analogs at marmoset, macaque, and human vasopressin 1a receptor.Biomed Pharmacother. 2020 Jun;126:110060. doi: 10.1016/j.biopha.2020.110060. Epub 2020 Mar 4. Biomed Pharmacother. 2020. PMID: 32145592 Free PMC article.
-
Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery.Front Neuroendocrinol. 2018 Oct;51:14-24. doi: 10.1016/j.yfrne.2017.10.004. Epub 2017 Oct 18. Front Neuroendocrinol. 2018. PMID: 29054552 Free PMC article. Review.
-
Molecular pharmacology of human vasopressin receptors.Adv Exp Med Biol. 1998;449:251-76. doi: 10.1007/978-1-4615-4871-3_34. Adv Exp Med Biol. 1998. PMID: 10026814
-
Molecular basis for agonist selectivity in the vasopressin/oxytocin receptor family.Adv Exp Med Biol. 1995;395:321-8. Adv Exp Med Biol. 1995. PMID: 8713982
-
Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8. Prog Brain Res. 2008. PMID: 18655903 Review.
Cited by
-
The Vasopressin 1b Receptor Antagonist A-988315 Blocks Stress Effects on the Retrieval of Object-Recognition Memory.Neuropsychopharmacology. 2015 Jul;40(8):1979-89. doi: 10.1038/npp.2015.48. Epub 2015 Feb 11. Neuropsychopharmacology. 2015. PMID: 25669604 Free PMC article.
-
Neuropeptides involved in the pathophysiology of schizophrenia and major depression.Neurotox Res. 2002 Aug-Sep;4(5-6):453-468. doi: 10.1080/10298420290031432. Neurotox Res. 2002. PMID: 12754159
-
Genetic vasopressin deficiency facilitates performance of a lateralized reaction-time task: altered attention and motor processes.J Neurosci. 2003 Feb 1;23(3):1066-71. doi: 10.1523/JNEUROSCI.23-03-01066.2003. J Neurosci. 2003. PMID: 12574437 Free PMC article.
-
Oxytocin and social cognition in rhesus macaques: implications for understanding and treating human psychopathology.Brain Res. 2014 Sep 11;1580:57-68. doi: 10.1016/j.brainres.2013.11.006. Epub 2013 Nov 11. Brain Res. 2014. PMID: 24231551 Free PMC article. Review.
-
Missing pieces in decoding the brain oxytocin puzzle: Functional insights from mouse brain wiring diagrams.Front Neurosci. 2022 Oct 26;16:1044736. doi: 10.3389/fnins.2022.1044736. eCollection 2022. Front Neurosci. 2022. PMID: 36389241 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous